Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris

LEO Pharma

Status and phase

Completed

Phase 2

Conditions

Acne Vulgaris

Treatments

Drug: marketed topical retinoid

Drug: vehicle gel

Drug: marketed topical NSAID

Study type

Interventional

Funder types

Industry

Identifiers

NCT01461655

LP0045-01

2011-000244-24 (EudraCT Number)

Details and patient eligibility

About

The aim of this proof of principle study is to evaluate efficacy and safety of the sequential application of two marketed products for the treatment of acne vulgaris, using the Split-Face model

Enrollment

40 patients

Sex

All

Ages

18 to 35 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects having understood and signed an informed consent form
Male or female subjects who are 18 to 35 years (both included) of age presenting acne vulgaris of the face.
A minimum of 10 inflammatory lesions (papules and pustules) on the entire face, and a minimum of 20 non-inflammatory lesions (open comedones and closed comedones) on the entire face.
Disease severity grade as mild or moderate according to the investigator's global assessment (grade 2 or grade 3)

Exclusion criteria

Females who are pregnant, of child-bearing potential and who wish to become pregnant during the study, or who are breast feeding.
Subjects with any acne cysts or more than one nodule per hemiface.
Subjects with acne conglobata, acne fulminans, secondary acne (e.g. chloracne, drug-induced acne), or any acne requiring systemic treatment.
Subjects with a dark pigmentation of the skin or skin type that may, in any way, confound interpretation of the study results (skin type V or VI on Fitzpatrick scale.
Subjects with other facial skin disorders that may interfere with study assessments.
Subjects who will use medicated cosmetics and/or soaps (including soaps containing antibacterial agents such as benzoyl peroxide, keratolytic agents such as salicylic acid, skin fresheners/astringents or aftershave products) on the face for the duration of the study.
Subjects with a history of actinic keratosis on the face or skin cancer.
Use of hormonal oral contraceptives for acne control for less than 6 months prior to the randomisation.
Subjects using one of the following systemic medication within 4 weeks before the randomisation and during the study, which could have an effect on the trial disease.
systemic corticosteroids,
anti-acne drugs,
oral retinoids
any immunosuppressive drugs.
Subjects using systemic NSAIDs (including aspirin) within 1 week before the randomisation and during the study.
Subjects using paracetamol within 1 week before the randomisation. Paracetamol will be allowed during the study with a maximum dose of 1g twice daily and for a maximum of 3 consecutive days
Subjects using one of the following topical medication within 2 weeks before the randomisation and during the study, which could have an effect on the trial disease:
anti-inflammatory drugs (e.g. topical corticosteroids, NSAIDs),
anti-acne drugs,
topical retinoids,
topical antibacterial agents
any topical immunosuppressive drugs.
Subjects with known or suspected hypersensitivity to component(s) of the investigational products or other nonsteroidal anti- inflammatory drug NSAIDs (e.g., aspirin, diclofenac, ibuprofen, ketoprofen).
Subjects with presence of any clinically significant gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting).
Subjects with known presence of active peptic ulcer.
Subjects with history (during the last 10 years) or known presence of asthma.
Subjects with history (during the last 5 years) or known presence of rhinitis or urticaria